Alkermes | Results Presentation Deck | 27 slides — playbook

Alkermes | Results Presentation Deck | 27 slides

Alkermes · 2023-10

arc beats above · slides in the middle · loops below · scroll → 0 LOOPS

Deck intelligence map

4

coverage by narrative range · generated from this deck JSON

Narrative range 22 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 6 hits

— 0/2 slides

50% 1/2 slides

— 0/2 slides

100% 2/2 slides

— 0/2 slides

Solution 6 slides 100% 6/6 slides 100% 6/6 slides · 23 hits

— 0/6 slides

50% 3/6 slides

— 0/6 slides

100% 6/6 slides

— 0/6 slides

Market Size 11 slides 100% 11/11 slides 100% 11/11 slides · 46 hits

— 0/11 slides

45.5% 5/11 slides · 6 hits 18.2% 2/11 slides 100% 11/11 slides

— 0/11 slides

Financials 3 slides 100% 3/3 slides 100% 3/3 slides · 6 hits

— 0/3 slides

66.7% 2/3 slides

— 0/3 slides

100% 3/3 slides

— 0/3 slides

Slide inventory

27

every slide · same image gating as the playbook

01

front_matter

Open slide detail

02

other

Open slide detail

03

transition

Open slide detailBeat · Problem

04

The slide highlights significant growth in revenue and net income metrics year-over-year.analyze_data

Open slide detailBeat · Problem

05

Includes a blue box highlight around the Q3'23 column.analyze_data

Open slide detail

06

Includes both GAAP and non-GAAP projections, plus specific product revenue breakdowns.analyze_data

Open slide detail

07

front_matter

Open slide detailBeat · Solution

08

The chart illustrates the revenue contribution of four specific products (VIVITROL, ARISTADA, VUMERITY, LYBALVI) over time.analyze_data

Open slide detailBeat · Solution

09

Includes a disclaimer regarding the forward-looking nature of the expectations.analyze_data

Open slide detailBeat · Solution

10

The chart tracks TRx (Total Prescriptions) over 101 weeks.analyze_data

Open slide detailBeat · Solution

11

analyze_data

Open slide detailBeat · Solution

12

analyze_data

Open slide detailBeat · Solution

13

front_matter

Open slide detailBeat · Market Size

14

summarize

Open slide detailBeat · Market Size

15

The slide illustrates the escalation of doses for both SAD and MAD study arms.present_framework

Open slide detailBeat · Market Size

16

SAD: Single Ascending Dose; MAD: Multiple Ascending Dose; AE: Adverse Event; SAE: Serious Adverse Event.summarize

Open slide detailBeat · Market Size

17

Includes box plots for AUC and Cmax across dose levels (1, 3, 8, 15, 25, 50 mg).analyze_data

Open slide detailBeat · Market Size

18

The diagram illustrates a 4-way cross-over design with 4 patients, each receiving a different sequence of placebo and three dose levels (1mg, 3mg, 8mg).present_framework

Open slide detailBeat · Market Size

19

The slide presents clinical trial baseline data for a very small sample size (N=4).analyze_data

Open slide detailBeat · Market Size

20

The table displays n (%) for adverse events related to the study drug.analyze_data

Open slide detailBeat · Market Size

21

Data represents NT1 patients; N=4 per dose; P-values indicate statistical significance vs placebo.analyze_data

Open slide detailBeat · Market Size

22

The chart uses a split x-axis to show pre-dose baseline and post-dose results. The 8mg dose maintains maximum sleep latency (40 min) for the duration of the tesanalyze_data

Open slide detailBeat · Market Size

23

summarize

Open slide detailBeat · Market Size

24

appendix

Open slide detailBeat · Financials

25

appendix

Open slide detailBeat · Financials

26

Includes specific line items for share-based compensation, depreciation, amortization, separation expense, tax effects, non-cash interest, and a Janssen arbitraanalyze_data

Open slide detailBeat · Financials

27

closing_ask

Open slide detail